Pluri (US:PLUR) Globenewswire·2025-12-09 13:30Core Viewpoint - Pluri Inc. has appointed Alejandro Weinstein as Chairman of the Board, aiming to strengthen its market position and unlock the value of its assets [1][2][4]. Leadership Transition - Alejandro Weinstein, a significant shareholder, will lead the company into its next growth phase, emphasizing strategic changes and value creation [2][4]. - Zami Aberman, the outgoing Chairman, will transition to Vice Chairman, continuing to support the company's strategic direction [3][4]. Financial Transactions - Pluri has entered into a Securities Purchase Agreement with Weinstein, involving the purchase of 625,000 common shares and warrants for a total of $2.5 million, intended for general working capital [4][6]. - The warrants have an exercise price of $4.25 per share and are exercisable until June 30, 2026 [4]. Shareholder Dynamics - Weinstein's ownership is expected to rise to approximately 30% of the issued and outstanding shares, reflecting his confidence in Pluri's asset base and long-term strategy [6]. Company Overview - Pluri Inc. is a biotechnology company focused on mass-scale cell expansion and biofarming, utilizing a patented 3D cell expansion platform [8]. - The company operates in regenerative medicine, foodtech, and agtech, aiming to address global challenges such as sustainable food production and healthcare [9].